⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
KEYTRUDA ® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
businesswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus Padcev ® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
businesswire.com
MRK
Head and Neck Cancer Therapeutics Market to Reach USD 2.6 Billion by 2032, Driven by Immunotherapy and Precision Oncology - Credence Research Inc.
prnewswire.com
MRK
BMY
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
businesswire.com
MRK
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
businesswire.com
MRK
PD-L1 Biomarker Testing Market Research Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031
globenewswire.com
MRK
Pharmaceutical Solvents Market Forecast 2026-2036: Market to Reach USD 7 Billion by 2036 at 4.6% CAGR | FMI Analysis
accessnewswire.com
AVTR
MRK
TMO
ASH
DOW
LYB
ECL
Synergis Adept wurde bei den G2 Best Software Awards 2026 als führende Plattform für das Management technischer Dokumente im Bereich CAD und PLM ausgezeichnet. USA - Deutsch USA - English USA - English APAC - English USA - Français USA - español
prnewswire.com
DOW
MRK
ED
GIS
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
businesswire.com
MRK
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
businesswire.com
MRK